Showing results (561-570 of 694) with videos related to
Sort By:
Pageof 70
European Journal of Pharmacology|November 16, 1993
Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of ratsR L Dundore, D M Clas, L T Wheeler, et al.Molecular Neurobiology|June 27, 2024
CDK5 Deficiency Does not Impair Neuronal Differentiation of Human Induced Pluripotent Stem Cells but Affects Neurite OutgrowthSofía Mucci, Giulia Solange Clas, Camila Paola Allio, et al.Physical Therapy|July 4, 2006
Effect of brisk walking in 1 or 2 daily bouts and moderate resistance training on lower-extremity muscle strength, balance, and walking performance in women who recently went through menopause: a randomized, controlled trialTuula-Maria Asikainen, Jaana H Suni, Matti E Pasanen, et al.Psychotherapy Research : Journal of the Society for Psychotherapy Research|January 24, 2018
Do emotion regulation, attentional control, and attachment style predict response to cognitive behavioral therapy for anxiety disorders? - an investigation in clinical settingsSara Kerstine Kaya Nielsen, Ida Hageman, Anders Petersen, et al.Neurology|October 29, 2017
Monitoring disease activity in multiple sclerosis using serum neurofilament light proteinLenka Novakova, Henrik Zetterberg, Peter Sundström, et al.Journal of Neurochemistry|April 21, 2018
Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MSLenka Novakova, Avadhesh Kumar Singh, Markus Axelsson, et al.Annals of Neurology|February 1, 2011
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Clas Malmeström, Markus Axelsson, et al.Proceedings of the National Academy of Sciences of the United States of America|May 28, 2020
Inflammation-related plasma and CSF biomarkers for multiple sclerosisJesse Huang, Mohsen Khademi, Lars Fugger, et al.JMIR Mental Health|November 3, 2025
Group Cognitive Behavioral Therapy With Virtual Reality Exposure Versus In-Vivo Exposure for Social Anxiety Disorder and Agoraphobia: Underpowered Results From the SoREAL Pragmatic Randomized Clinical TrialBenjamin Arnfred, Fatime Zeka, Carsten Hjorthøj, et al.Annals of Neurology|April 3, 2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis patientsPeter Alping, Thomas Frisell, Lenka Novakova, et al.Pageof 70